356 related articles for article (PubMed ID: 9042265)
1. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA
Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors.
Healy DL; Burger HG; Mamers P; Jobling T; Bangah M; Quinn M; Grant P; Day AJ; Rome R; Campbell JJ
N Engl J Med; 1993 Nov; 329(21):1539-42. PubMed ID: 8413476
[TBL] [Abstract][Full Text] [Related]
3. [Role of total inhibin in diagnosis and monitoring of ovarian cancer in postmenopausal women].
Markova D; Milchev N; Batashki I; Uchikov A
Akush Ginekol (Sofiia); 2008; 47(1):16-9. PubMed ID: 18642569
[TBL] [Abstract][Full Text] [Related]
4. Characterization of inhibin forms and their measurement by an inhibin alpha-subunit ELISA in serum from postmenopausal women with ovarian cancer.
Robertson DM; Stephenson T; Pruysers E; McCloud P; Tsigos A; Groome N; Mamers P; Burger HG
J Clin Endocrinol Metab; 2002 Feb; 87(2):816-24. PubMed ID: 11836327
[TBL] [Abstract][Full Text] [Related]
5. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
[TBL] [Abstract][Full Text] [Related]
6. [Comparative evaluation of diagnostic significance of carbohydrate antigen CA125 and cancer-embryonal antigen in ovarian cancer].
Lapchenkov VI; Dudarev AL; Vinokurov VL; Iurkova LE; Barbanel EIu
Vestn Rentgenol Radiol; 1993; (5):30-1. PubMed ID: 7801580
[TBL] [Abstract][Full Text] [Related]
7. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
8. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
9. Total inhibin is a potential serum marker for epithelial ovarian cancer.
Tsigkou A; Marrelli D; Reis FM; Luisi S; Silva-Filho AL; Roviello F; Triginelli SA; Petraglia F
J Clin Endocrinol Metab; 2007 Jul; 92(7):2526-31. PubMed ID: 17473066
[TBL] [Abstract][Full Text] [Related]
10. [Inhibin and ovarian cancer].
Burger HG; Baillie A; Drummond AE; Healy DL; Jobling T; Mamers P; Robertson DM; Susil B; Cahir N; Shen Y; Verity K; Fuller PJ; Groome NP; Findlay JK
Vopr Onkol; 1999; 45(4):369-73. PubMed ID: 10532093
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
[TBL] [Abstract][Full Text] [Related]
12. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of CEA and CA125 regarding relapse and metastasis in resectable non-small cell lung cancer.
Gaspar MJ; Diez M; Rodriguez A; Ratia T; Martin Duce A; Galvan M; Granell J; Coca C
Anticancer Res; 2003; 23(4):3427-32. PubMed ID: 12926084
[TBL] [Abstract][Full Text] [Related]
14. Inhibin as a diagnostic marker for ovarian cancer.
Robertson DM; Pruysers E; Jobling T
Cancer Lett; 2007 Apr; 249(1):14-7. PubMed ID: 17320281
[TBL] [Abstract][Full Text] [Related]
15. Multiple immunoreactive inhibin proteins in serum from postmenopausal women with epithelial ovarian cancer.
Lambert-Messerlian GM; Steinhoff M; Zheng W; Canick JA; Gajewski WH; Seifer DB; Schneyer AL
Gynecol Oncol; 1997 Jun; 65(3):512-6. PubMed ID: 9190984
[TBL] [Abstract][Full Text] [Related]
16. Significance of some tumor markers in differential diagnosis of ovarian tumor.
Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
[TBL] [Abstract][Full Text] [Related]
17. Significance of tumor marker determinations in the primary therapy of ovarian cancer.
Meier W; Baumgartner L; Stieber P; Hasholzner U; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):2949-51. PubMed ID: 9329572
[TBL] [Abstract][Full Text] [Related]
18. Inhibins and ovarian cancer.
Robertson DM; Pruysers E; Burger HG; Jobling T; McNeilage J; Healy D
Mol Cell Endocrinol; 2004 Oct; 225(1-2):65-71. PubMed ID: 15451569
[TBL] [Abstract][Full Text] [Related]
19. Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women.
Serin IS; Tanriverdi F; Yilmaz MO; Ozcelik B; Unluhizarci K
Gynecol Endocrinol; 2008 Mar; 24(3):117-21. PubMed ID: 18335323
[TBL] [Abstract][Full Text] [Related]
20. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
Moore RG; Brown AK; Miller MC; Skates S; Allard WJ; Verch T; Steinhoff M; Messerlian G; DiSilvestro P; Granai CO; Bast RC
Gynecol Oncol; 2008 Feb; 108(2):402-8. PubMed ID: 18061248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]